두개강내 병변에서 Technetium-99m-MIBI SPECT의 활용
Technetium-99-m-MIBI SPECT in Intracranial Lesions
소속 상세정보
박성찬
홍용길/성우현/이경진/박영섭/백민우/강준기/최창락
KMID : 0359819940230050548
Abstract
Thallium (T1) has recently been used as a pharmaceutical for tumor imaging and staging. The aim of this study was to evaluate the clinical significance of the T1 analogue, 99m-TcMIBI (methoxyisobutylisonitrile), for imaging of intracranial
lesions.
The
advantages of MIBI were thought to be a lower radiation exposure and better image quality than with T1.
99m-Tc-MIBI SPECT studies were done in 30 patients with brain tumors (14 astrocytomas, 7 meningiomas, 2 hemangioblastomas, 2 craniopharyngiomas, 1 ependymoma, 4 metastatic tumors) and in twelve patients with non-tumorous lesions (2 abscesses, 2
granulomas, 2 cysticercosis, 3 old intracerebral hemorrages, 1 infarction, 1 postoperative gliosis, 1 unknown pathology), and semiquantitative assessment of tracer uptake was made using a ratio of radioactivity for lesion to contralateral normal
brain
(Lesion/Contralateral normal brain ; L/C).
Twenty six of thirty tumors showed high L/C ratios (>1.5) and another four tumors low L/C ratios (<1.5). Of 12 non-tumorous intracranial lesions, 11 showed little or no uptake, but one moderate uptake.
In conclusion, it appears that rain tumors show more intense focal uptake than non-tumorous brain lesion. However, further studies would be warranted to evaluate the clinical significance of MIBI SPECT in tumor staging (grading) and in
differentiating
necrosis from tumor regrowth more clearly.
키워드
원문 및 링크아웃 정보
등재저널 정보